Abstract
Thorough understanding of the complex interactions between components of immunological response has led to the arousal of the concept of immune-mediated anti-cancer therapy. Although, the use of monoclonal antibodies (MAbs) in hematological malignancies met with success, therapy of solid tumors has been impeded by many obstacles. Some MAbs have increased the efficacy of treatment of certain tumors with acceptable adverse events. Trastuzumab, cetuximab and bevacizumab have become FDA approved for the treatment of breast and colorectal cancer, respectively. The dosing strategies, timing and schedule of antibody administration, duration of treatment are yet to be determined under specific circumstances. Combinations with other biologic agents, such as small-molecule inhibitors of the same pathway would be really useful. Multimodality approaches are based on synergistic effects observed with the combination of antibodies with chemotherapeutic drugs and/or radiotherapy. Immune-mediated effects may be further exploited with the use of bivalent (bispecific) molecules, while radioimmunotherapy via radiolabelling of the antibody is feasible. Modified recombinant antibodies could be applied for toxin delivery to tumor cells, while molecules fused with drugactivating enzymes can mediate prodrug therapy. Increased penetrability into tumors can also be achieved with novel antibody fragments. In the future, better selection of patient subpopulations with tumors overexpressing disease-related clinical biomarkers could result in an increase in both efficacy and specificity of antibody-based treatment.
Keywords: Antibody, HER2/neu, EGFR, VEGF, trastuzumab, cetuximab, bevacizumab, immunotherapy
Current Topics in Medicinal Chemistry
Title: Monoclonal Antibodies in the Management of Solid Tumors
Volume: 6 Issue: 16
Author(s): Haralambos P. Kalofonos and Petros D. Grivas
Affiliation:
Keywords: Antibody, HER2/neu, EGFR, VEGF, trastuzumab, cetuximab, bevacizumab, immunotherapy
Abstract: Thorough understanding of the complex interactions between components of immunological response has led to the arousal of the concept of immune-mediated anti-cancer therapy. Although, the use of monoclonal antibodies (MAbs) in hematological malignancies met with success, therapy of solid tumors has been impeded by many obstacles. Some MAbs have increased the efficacy of treatment of certain tumors with acceptable adverse events. Trastuzumab, cetuximab and bevacizumab have become FDA approved for the treatment of breast and colorectal cancer, respectively. The dosing strategies, timing and schedule of antibody administration, duration of treatment are yet to be determined under specific circumstances. Combinations with other biologic agents, such as small-molecule inhibitors of the same pathway would be really useful. Multimodality approaches are based on synergistic effects observed with the combination of antibodies with chemotherapeutic drugs and/or radiotherapy. Immune-mediated effects may be further exploited with the use of bivalent (bispecific) molecules, while radioimmunotherapy via radiolabelling of the antibody is feasible. Modified recombinant antibodies could be applied for toxin delivery to tumor cells, while molecules fused with drugactivating enzymes can mediate prodrug therapy. Increased penetrability into tumors can also be achieved with novel antibody fragments. In the future, better selection of patient subpopulations with tumors overexpressing disease-related clinical biomarkers could result in an increase in both efficacy and specificity of antibody-based treatment.
Export Options
About this article
Cite this article as:
Kalofonos P. Haralambos and Grivas D. Petros, Monoclonal Antibodies in the Management of Solid Tumors, Current Topics in Medicinal Chemistry 2006; 6 (16) . https://dx.doi.org/10.2174/156802606778194208
DOI https://dx.doi.org/10.2174/156802606778194208 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry Chemotherapeutic Targeting of Cell Death Pathways
Anti-Cancer Agents in Medicinal Chemistry Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy Inhibition of Proliferation and Induction of Apoptosis by Thymoquinone via Modulation of TGF Family, p53, p21 and Bcl-2α in Leukemic Cells
Anti-Cancer Agents in Medicinal Chemistry Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?
Anti-Cancer Agents in Medicinal Chemistry Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma
Current Cancer Drug Targets Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Author Index To Volume 3
Current Topics in Medicinal Chemistry Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets A Review of Evaluating Hematopoietic Stem Cells Derived from Umbilical Cord Blood's Expansion and Homing
Current Stem Cell Research & Therapy DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Recent Concise Viewpoints of Chronic Active Epstein-Barr Virus Infection
Current Pediatric Reviews PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism